DBV Technologies Stock Breaks Its €2.75 Support Ahead of Semi-Annual Results
The French biotech company is trending downwards during the session, contrary to a nearly stable SBF 120. The stock is among the largest declines of the broad index, on the eve of its semi-annual earnings release. Today's movement continues a downward trend observed since spring.
The Stock Breaks Its €2.75 Support and Trades Below Its Three Moving Averages
DBV Technologies stock is down 3.03% at €2.748 during the session, with a volume that pushes it among the largest declines in the SBF 120. The stock broke its €2.75 support during the session and remains just below, extending the bearish momentum observed for several weeks. The price is trading 3.58% below its MM20 (€2.85) and nearly 13% below its MM200 (€3.15), indicating that the selling pressure is sustained.
The RSI at 45 remains neutral, showing no extremes at this stage. Over three months, the biotech has fallen nearly 29%, although it still shows a gain of more than 60% over one year.
Semi-Annual Accounts Expected Tomorrow, in a Case Dominated by the FDA Schedule
The decline occurs on the eve of the first semester results announcement, scheduled for July 16, 2026. This deadline focuses attention on the cash position and the progress of preparatory work for the U.S. regulatory filing. At the end of June, the company confirmed its aim to submit its biologics license application to the FDA for Viaskin Peanut in the third quarter of 2026, without requesting additional data from the Agency.
Since then, the stock price has fluctuated around the €2.75 threshold, with sharp movements: a rebound of 4% on July 8, a decline of 3.5% on July 6, and an increase of 5.5% on July 3. The technical support break of the day calls for attention on the semi-annual publication.
